Cost-effectiveness of lowering blood pressure with a fixed combination of perindopril and indapamide in type 2 diabetes mellitus: An ADVANCE trial-based analysis

Medical Journal of Australia

Volumn 193, Issue 6, 2010, Pages 320-324

  Glasziou, Paul P ^a   Clarke, Philip ^b   Alexander, Jan ^c   Rajmokan, Mohana ^d   Beller, Elaine ^c   Woodward, Mark ^b,e   Chalmers, John ^b,e   Poulter, Neil ^f   Patel, Anushka ^e  

^a BOND UNIVERSITY   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c UNIVERSITY OF QUEENSLAND   (Australia)

^d QUEENSLAND HEALTH   (Australia)

^e GEORGE INSTITUTE FOR INTERNATIONAL HEALTH   (Australia)

^f IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GLICLAZIDE; INDAPAMIDE; INDAPAMIDE PLUS PERINDOPRIL; PERINDOPRIL; PLACEBO; ANTIHYPERTENSIVE AGENT;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; ECONOMIC EVALUATION; FEMALE; HEALTH CARE UTILIZATION; HEART MUSCLE REVASCULARIZATION; HOSPITAL ADMISSION; HOSPITAL COST; HOSPITALIZATION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTPATIENT CARE; PROSPECTIVE STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; AUSTRALIA; COST BENEFIT ANALYSIS; DIABETIC ANGIOPATHIES; DRUG EFFECTS; ECONOMICS; LIFE EXPECTANCY;

ANTIHYPERTENSIVE AGENTS; AUSTRALIA; BLOOD PRESSURE; COST-BENEFIT ANALYSIS; DIABETIC ANGIOPATHIES; HOSPITAL COSTS; HUMANS; HYPERTENSION; INDAPAMIDE; LIFE EXPECTANCY; PERINDOPRIL; QUALITY OF LIFE;

EID: 77957674852     PISSN: 0025729X     EISSN: 13265377     Source Type: Journal    
DOI: 10.5694/j.1326-5377.2010.tb03941.x     Document Type: Article

References (18)

1. Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27: 1047-1053.
2. Turnbull F, Neal B, Pfeffer M, et al. Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system. J Hypertens 2007; 25: 951-958.
3. Gu D, Reynolds K, Wu X, et al; InterASIA Collaborative Group. Prevalence, awareness, treatment, and control of hypertension in China. Hypertension 2002; 40: 920-927.
4. Ong KL, Cheung BM, Man YB, et al. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004. Hypertension 2007; 49: 69-75.
5. Patel R, Lawlor DA, Whincup P, et al. The detection, treatment and control of high blood pressure in older British adults: cross-sectional findings from the British Women's Heart and Health Study and the British Regional Heart Study. J Hum Hypertens 2006; 20: 733-741.
6. Baker S, Priest P, Jackson R. Using thresholds based on risk of cardiovascular disease to target treatment for hypertension: modelling events averted and number treated. BMJ 2000; 320: 680-685.
7. Asia Pacific Cohort Studies Collaboration, Kengne AP, Patel A, Barzi F, et al. Systolic blood pressure, diabetes and the risk of cardiovascular diseases in the Asia-Pacific region. J Hypertens 2007; 25: 1205-1213.
8. Patel A, MacMahon S, Chalmers J, et al: ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007; 370: 829-840.
9. Rationale and design of the ADVANCE study: a randomised trial of blood pressure lowering and intensive glucose control in high-risk individuals with type 2 diabetes mellitus. Action in diabetes and vascular disease: preterax and diamicron modified-release controlled evaluation. J Hypertens Suppl 2001; 19: S21-28.
10. Study rationale and design of ADVANCE: action in diabetes and vascular disease - preterax and diamicron MR controlled evaluation. Diabetologia 2001; 44: 1118-1120.
11. Gudex C, Kind P. The QALY toolkit. (Discussion paper 38.) York: University of York, Centre for Health Economics, 1988.
12. Ware JE, Kosinski M, Dewey J. How to score version two of the SF-36 health survey. Lincoln, RI: QualityMetric Incorporated, 2000.
13. Glasziou P, Alexander J, Beller E, Clarke P. Which health-related quality of life score? A comparison of alternative utility measures in patients with type 2 diabetes in the ADVANCE trial. Health Qual Life Outcomes 2007; 5: 21.
14. Department of Health and Ageing. National Hospital Cost Data Collection (NHCDC) reports. 2007. Round 11 cost weights, peer group report and hospital reference manual for 2006-07. Canberra: DoHA, 2008. http://www.health.gov.au/ internet/main/publishing.nsf/Content/health-casemix-data-collections- NHCDCReports (accessed Dec 2007).
15. Dolan P, Roberts J. Modelling valuations for Eq-5d health states: an alternative model using differences in valuations. Med Care 2002; 40: 442-446.
16. Clarke PM, Glasziou P, Patel A, et al. Event rates, hospital utilization and costs associated with major complications of diabetes: multicountry comparative analysis. PLoS Med 2010; 7: e1000236. doi: 10.1371/journal.pmed. 1000236.
17. Raikou M, Gray A, Briggs A, et al; UK Prospective Diabetes Study Group. Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40. BMJ 1998; 317: 720-726.
18. Briggs A, Mihaylova B, Sculpher M, et al; EUROPA Trial investigators. Cost effectiveness of perindopril in reducing cardiovascular events in patients with stable coronary artery disease using data from the EUROPA study. Heart 2007; 93: 1081-1086.